Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Key facts

Sponsor

Chinese Academy of Medical Sciences

Principal Investigator

Shunan M Qi, MD

Chinese Academy of Medical Sciences

Intervention

Anti-PD-1 monoclonal antibody(drug)

Enrollment

54 enrolled

Eligibility

18-70 years · All sexes

Timeline

2021 – 2024

Study locations (1)

• National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality, China

Collaborators

Peking University Cancer Hospital & Institute · The Affiliated Hospital Of Guizhou Medical University · The First Hospital of Jilin University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Extranodal nasal NK/T cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07380984
  PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
  Ruijin Hospital
• RECRUITINGPHASE1, PHASE2NCT06966154
  A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
  Fudan University
• RECRUITINGPHASE2NCT07000617
  A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
  Peking University Cancer Hospital & Institute
• RECRUITINGPHASE1NCT06732492
  RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• ENROLLING BY INVITATIONNCT07450040
  Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
  Eye & ENT Hospital of Fudan University
• RECRUITINGPHASE1, PHASE2NCT06559553
  "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
  Mingzhi Zhang
• RECRUITINGPHASE2NCT06824883
  Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
  Peking Union Medical College Hospital
• RECRUITINGPHASE1, PHASE2NCT06376721
  Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
  Beijing Tongren Hospital

See all trials for Extranodal nasal NK/T cell lymphoma →